BCP's Strong Surge: 36% Profit Growth in Q2 2023

The company's net profit increased by 36% to Rs. 151 crore from Rs.1500 lakhs The Company’s total revenue saw a 9% increase to Rs. 809 crore is the written form of 8.09 billion in Indian numbering system. "EPS has been adjusted following the subdivision of shares from Rs.” In September 2023, the price has increased to Rs. 1 each. The price is Rs. 9.72. The time is 7:19 at the end of the period. Henceforth, the earnings per share for the comparable periods have been calculated using the adjusted number of outstanding shares for each period, which was increased due to share sub-division. The domestic sales saw a rise of 11 per cent, reaching Rs. 481 crore in Indian Rupees. The international sales increased by 7.1 percent to Rs. 434 crore. 401 crore from 1 Rupee.

The business experienced double-digit growth in the second quarter, with the exception of South Africa the Row exports business achieved robust growth. In addition to a strong presence in India, where it generates the majority of its revenue, the company also operates in Russia and South Africa as its other two key markets. The company has six brands that rank among the top 300 IPM brands in India. The changes we've made to our go-to-market strategy are resulting in increased market share and better rankings in IPM. The portfolio we have gained has not only allowed us to expand our presence in the chronic segment , but also improve our market rankings. However, it is also starting to have a positive effect on our operating margins . Substantial advancements have been achieved in the field of cardiology. Despite relatively softer demand in the acute segment, our domestic business demonstrated strong resilience.